Cargando…
MEDB-56. POx NPs mediated delivery of (TLR7/8) agonist resiquimod improves treatment outcomes in SHH medulloblastoma by targeting tumor associated macrophages
Cancer immunotherapy, the utilization of the patients’ own immune system to treat cancer, has emerged as a powerful new strategy in cancer treatment. Recent clinical data has demonstrated immunotherapy to be effective in a wide range of cancers, including lung, bladder, renal cell, colorectal, gastr...
Autores principales: | Hwang, Duhyeong, Alicea, Coral del Mar, Lim, Chaemin, Park, Christopher, Gershon, Timothy, Sokolsky-Papkov, Marina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165126/ http://dx.doi.org/10.1093/neuonc/noac079.430 |
Ejemplares similares
-
MEDB-48. Infant medulloblastoma - SHH subtype – with residual disease. To treat or not to treat
por: Dahl, Christine, et al.
Publicado: (2022) -
MEDB-66. Investigating intra-tumoral heterogeneity of extrachromosomal DNA in SHH medulloblastoma
por: Chapman, Owen, et al.
Publicado: (2022) -
MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?
por: Erker, Craig, et al.
Publicado: (2022) -
MEDB-22. iPSC-derived cerebellar organoid model for hereditary genetic predisposition in SHH-medulloblastoma
por: Manz, Frederik, et al.
Publicado: (2022) -
MEDB-15. Dynamic chromatin alteration induces oncogenic hijacking by essential transcriptional factors during SHH medulloblastoma tumorigenesis
por: Shiraishi, Ryo, et al.
Publicado: (2022)